Background: We report on 3 cases of membranoproliferative glomerulonephritis associated with mixed cryoglobulin in patients with hepatitis C virus (HCV) antibodies but a negative blood viral load. These cases explore the pathogenesis of the renal disease. Methods: We searched for occult HCV infection in peripheral blood mononuclear cells, cryoprecipitate, bone marrow cells, and glomeruli using ultrasensitive PCR assays and immunohistochemistry. We also looked for infraclinical B cell lymphoma by computed tomodensitometry, bone marrow aspiration and biopsy, and lymphocyte typing. Results: By PCR assays, we did not evidence occult hepatitis C infection in peripheral blood mononuclear cells, bone marrow cells, or cryoprecipitates. In the only patient with available kidney specimen, we evidenced HCV-NS3 antigen in glomeruli. HCV-associated lymphoma was excluded, but mild polyclonal B lymphocytosis was present in the 3 patients. Remission occurred spontaneously in 1 patient, and in another patient it occurred after rituximab treatment. The third patient was lost to follow-up. Conclusions: In patients with hepatitis C-negative viral load, membranoproliferative glomerulonephritis could be induced by the persistence of HCV antigen in the kidney but not in hematopoietic cells. Nonlymphomatous B cell proliferation may also be induced by chronic viral stimulation.

Keywords:
Membranoproliferative glomerulonephritis, Hepatitis C virus, Cryoglobulinemia, B lymphocyte, HCV-NS3 antigen
1.
Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, et al: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465–470.
2.
Cacoub P, Musset L: Mixed cryoglobulinemia. Rev Prat 2000;50:276–280.
3.
Kamar N, Izopet J, Alric L, et al: Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008;69:149–160.
4.
Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Valla D, Piette JC, et al: Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291–1300.
5.
El-Serag HB, Hampel H, Yeh C, Rabeneck L: Extra hepatic manifestations of hepatitis C among United States Male Veterans. Hepatology 2002;36:1439–1445.
6.
Licht C, Schlötzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B: MPGN II – genetically determined by defective complement regulation? Pediatr Nephrol 2007;22:2–9.
7.
Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M: Biological and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775–778.
8.
Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, Cacoub P: Relapse of hepatitis C virus associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58:604–611.
9.
Harle JR, Disdier P, Durand JM, Alessi MC, Boucraut J, Rouseau J, Kaplanski G, Weiller PJ: Mixed cryoglobulinemia in hepatitis C virus infection. 10 cases. Presse Med 1991;20:1233.
10.
Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V: Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7–14.
11.
Castillo I, Rodriguez-Inigo E, Bartolomé J, de Lucas S, Ortíz-Movilla N, López-Alcorocho JM, Pardo M, Carreño V: Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005;54:682–685.
12.
Pham TN, Michalak TI: Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008;14:2789–2793.
13.
Halfon P, Martinot-Peignoux M, Cacoub P: The myth of occult hepatitis C infection. Hepatology 2009;50:1675.
14.
Giannini C, Petrarca A, Monti M, Arena U, Caini P, Solazzo V, Gragnani L, Milani S, Laffi G, Zignego AL: Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood 2008;111:2943–2945.
15.
Levine JW, Gota C, Fessier BJ, Calabrese LH, Cooper SM: Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005;32:1164–1167.
16.
Halfon P, Bourlière M, Ouzan D, Sène D, Saadoun D, Khiri H, Pénaranda G, Martineau A, Oulès V, Cacoub P: Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol 2008;46:2106–2108.
17.
Levey AS, Bosch JP, Breyer Lewis J, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–470.
18.
Welker MW, Zeuzem S: Occult hepatitis C: how convincing are the current data? Hepatology 2009;49:665–675.
19.
Cao Y, Zhang Y, Wang S, Zou W: Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis. Nephrol Dial Transplant 2009;24:2745–2751.
20.
Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena FP, Dammacco F: Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005;140:498–506.
21.
Nepomnyashchikh GI, Aidagulova SV, Nepomnyashchikh DL, Tolokonskaya NP, Karavaeva YY, Sakharova EG, Mezentseva GA, Batemirova EV: Immunohistochemichal, molecular, and pathomorphological study of liver biopsy specimens during chronic hepatitis C. Bull Exp Biol Med 2002;134:307–311.
22.
Sène D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P: Hepatitis C virus-associated B-cell proliferation – the role of serum B lymphocyte stimulator (BLys/BAFF). Rheumatology 2007;46:65–69.
23.
Landau DA, Saadoun D, Calabrese LH, Cacoub P: The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007;6:581–587.
24.
Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, Foretova L, Cocco PL, Staines A, Vornanen M, Whitby D, Boffetta P, Becker N, De Sanjosé S: Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131:1879–1886.
25.
Cocco PL, Piras G, Monne M, Uras A, Gabbas A, Ennas MG, Palmas A, Murineddu M, Collu S, Melis M, Rais M, Todde P, Cabras MG, Angelucci E, Massarelli G, Nieters A: Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 2008;87:474–483.
26.
Schöllkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, Chang ET, Glimelius B, Porwit A, Sundström C, Hansen M, Adami HO, Melbye M: Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885–1890.
27.
De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M: Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggest that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000;96:3578–3584.
28.
Ferri S, Dal Pero F, Bortoletto G, Bianchi FB, Lenzi M, Alberti A, Gerotto M: Detailed analysis of the E2-IgM complex in hepatitis C-related type II mixed cryoglobulinaemia. J Viral Hepat 2006;13:166–176.
29.
Zehender G, De Maddalena C, Bernini F, Ebranati E, Monti G, Pioltelli P, Galli M: Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol 2005;79:9145–9156.
30.
Maruyama S, Hirayama C, Horie Y, Yorozu K, Maeda K, Inoue M, Fujii Y, Umeki K, Koda M: Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome. Hepatogastroenterology 2007;54:493–498.
31.
Carbone A, Manconi R, Poletti A, Tirelli U, De Paoli P, Santini G, Diodato S, Manconi PE, Grigoletto E, Santi L, et al: Lymph node immunohistology in intravenous drug abusers with persistent generalized lymphadenopathy. Arch Pathol Lab Med 1985;109:1007–1012.
32.
Haydey RP, Patarroyo de Rojas M, Gigli I: A newly described control mechanism of complement activation in patients with mixed cryoglobulinemia (cryoglobulins and complement). J Invest Dermatol 1980;74:328–332.
33.
Saadoun D, Sadallah S, Trendelenburg M, Limal N, Sene D, Piette JC, Schifferli JA, Cacoub P: Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol 2006;145:308–312.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.